The APERITIF randomized clinical trial found that adding low-dose rivaroxaban to dual antiplatelet therapy (DAPT) did not significantly reduce the incidence of left ventricular thrombus at one month in anterior STEMI patients, while significantly increasing the risk of minor bleeding events.